| 摘要 |
Known 5-HT3 antagonists of specified formulae, e.g. (endo)-N-[[8-methyl-8-azabicyclo[3.2.1]octan-3-yl)amino]carbonyl]-2-(cyclopropylmethoxy)benzamide or (endo)-1-cyclohexyl-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-4(1H)oxo-quinoline-3-carboxamide or a pharmaceutically acceptable salt thereof, are administered topically for the treatment of peripheral disorders associated with pain. |
